SEC For	m 4																	
FORM 4 UNITED S					ATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549										OMB APPROVAL			
Section 16. Form 4 or Form 5 obligations may continue. See					d pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940										OMB Number:   3235-0287     Estimated average burden      hours per response:   0.5			
1. Name and Address of Reporting Person* <u>PALEKAR ROHAN</u>					2. Issuer Name <b>and</b> Ticker or Trading Symbol <u>Neoleukin Therapeutics, Inc.</u> [ NLTX ]								5. Relationship of Reporting R (Check all applicable) X Director			10% Owner		
(Last) (First) (Middle) C/O NEOLEUKIN THERAPEUTICS, INC.						3. Date of Earliest Transaction (Month/Day/Year) Officer ( 05/12/2022									(give title Other (specify below)			
188 EAST BLAINE STREET, #450 (Street) SEATTLE WA 98102					4. 11	4. If Amendment, Date of Original Filed (Month/Day/Year) 4. If Amendment, Date of Original Filed (Month/Day/Year) 5. Individual or Joint/Group Filing (Check Applic Line) X Form filed by One Reporting Person Form filed by More than One Reportin Person												
(City) (State) (Zip)																		
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																	
1. Title of Security (Instr. 3) Date (Month/D					) Day/Year) i		2A. Deemed Execution Date if any (Month/Day/Yea		Code (Ins				Beneficia Owned F	es ally Following	Form (D) or	n: Direct or or Indirect Enstr. 4)	of Indirect	
									Code V	Amount	(A) or (D)	Price	Price Reported Transaction (Instr. 3 and					
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned   (e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution D if any (Month/Day/	ate, Tr	ransaction ode (Instr.		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exerc Expiration Da (Month/Day/N	ate	) of Securities Underlying Derivative Sec (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Numbe derivative Securities Beneficia Owned Following Reported Transactie (Instr. 4)	e O s F ally D g (I	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				C	ode	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares						
Stock Option (Right to Buy)	\$1.07	05/12/2022			A		25,000		(1)	05/11/2032	Common Stock	25,000	\$0.00	25,00	0	D		

Explanation of Responses:

1. The option vests as to 1/12 of the total shares monthly beginning June 12, 2022 until the option is fully vested on May 12, 2023, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

## Remarks:

<u>/s/ Sean Smith, Attorney</u>	<u>-in-</u>
Fact for Rohan Palekar	

05/16/2022

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.